Dietary fats continue to attract attention in diabetes research, not only because of their role in energy intake, but also because different oils contain distinct bioactive compounds. A study recently published in Nutrire examined whether extra virgin rice bran oil supplementation could provide additional benefits for people with type 2 diabetes who were already following a standard diet in which olive oil was the main fat source.

The randomized, double-blind clinical trial enrolled 50 adults with type 2 diabetes. Participants received either 1 g/day of extra virgin rice bran oil capsules or a placebo for 12 weeks while maintaining the prescribed dietary pattern. The researchers evaluated a range of outcomes, including glucose metabolism, insulin resistance, lipid profiles, antioxidant status, and indices associated with cardiometabolic risk. 

Among the 46 participants who completed the study, the rice bran oil group showed lower fasting blood glucose levels compared with the placebo group. The intervention was also associated with improvements in several markers linked to insulin resistance, including METS-IR, TyG index, and TyG-BMI. These findings suggest that rice bran oil may influence metabolic pathways relevant to diabetes management, although not all measures changed to the same extent.

Phytochemicals
The study also reported increases in antioxidant capacity and superoxide dismutase activity, alongside reductions in total cholesterol, LDL cholesterol, and the atherogenic index. Rice bran oil is known to contain compounds such as γ-oryzanol and other phytochemicals that have been investigated for their potential antioxidant and lipid-modulating properties, making these observations particularly interesting for researchers studying the relationship between dietary fats and metabolic health. 

At the same time, several outcomes remained unchanged. The intervention did not lead to significant between-group differences in HbA1c, postprandial glucose, triglycerides, or body mass index. These results provide a useful reminder that improvements in some metabolic markers do not automatically translate into changes across all clinically relevant endpoints, especially within a relatively short intervention period.

The authors note important limitations, including the modest sample size and the 12-week duration of the trial. As a result, the findings should be viewed as preliminary rather than definitive. Larger and longer-term studies will be needed to determine whether the observed improvements can be replicated and whether they lead to meaningful clinical benefits over time. Even so, this work adds to the growing body of research exploring how specific dietary oils and their bioactive components may contribute to metabolic health in people with type 2 diabetes.

Image source: pxhere 

Text was created with the assistance of AI.